It is also well established that several antipsychotics can cause metabolic disorders such as hypertriglyceridemia, glucose dysregulation and elevated cholesterol levels, which is attributed to transcriptional activation of cholesterol and fatty acid biosynthetic genes via SREBP1 and SREBP2 (Cai et al, 2015; Ferno et al, 2005; Ferno et al, 2006; Pillinger et al, 2020). This evidence concerns the gene SREBF1 and metabolic disease.